'Market will see the value' in Imugene share price

Imugene shares might be in a slump, but the CEO is not giving up now.

| More on:
Two happy scientists analysing test results.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

During the past 12 months, the S&P/ASX 200 Index (ASX: XJO) has dealt out an 8.1% return before dividends. Yet, the Imugene Limited (ASX: IMU) share price — an index constituent — has not seen anywhere near as positive of a performance.

Shares in the clinical-stage immuno-oncology company have painfully fallen 62% this past year. A staggering $760 million in market capitalisation has been stripped away, leaving Imugene at a value of $572 million today.

The discouraging move is hardly due to a lack of announcements. In total, 40 price-sensitive releases have been made by Imugene since this time last year. Still, the continuous flow of developments left the share price seemingly unphased.

So, why is the company's CEO adamant there will be better times ahead for shareholders?

Industry in a slump

On 6 July, Imugene CEO Leslie Chong issued a letter to shareholders. Chong noted no improvement in the broader biotechnology sector globally and within Australia in the letter.

A claim backed up by the weakness demonstrated across even the biggest biotech companies in the world. Take, for example, Pfizer Inc (NYSE: PFE) and AbbVie Inc (NYSE: ABBV) — two stalwarts of the industry — each carrying share price declines of more than 11% over the last year.

What is remarkable is that both of the abovementioned biotechs generate tens of billions of dollars each year in revenue. In addition, these are highly profitable businesses — not little drug developers still looking to land a moneymaker.

There are a few factors that could be at play here. However, the most impactful element for the Imugene share price is arguably the company's pre-product stage. According to the company's most recent presentation, all its programs are in phase II trials or earlier.

This creates an additional layer of risk for investors in an environment where 'risk-free' returns from bonds are much more attractive. As a result, capital is less inclined to flow toward the likes of Imugene until it provides improved signs of a return on investment (ROI).

However, the CEO highlighted her team's belief that "the market will see the value of our company and the opportunity in the share price."

What could drive the Imugene share price higher?

Being a clinical-stage biotech, the company's share price movement can depend highly on trial findings. Hence, any indication of positive outcomes from Imugene's various programs could bolster the share price.

In June, Imugene announced that the HER-Vaxx therapy had induced antibodies. The antibody response correlated with tumour reduction. The Imugene share price lifted 2.25% on the release day.

Furthermore, shareholders will undoubtedly want to see the company's other programs progressing from phase I to II. Fortunately, Imugene remains well funded with more than $150 million in cash at its disposal.

Should you invest $1,000 in Imugene Limited right now?

Before you buy Imugene Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Imugene Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Pfizer. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Healthcare Shares

Guess which ASX 200 stock is jumping 16% on big news

Let's find out what news is getting investors excited this afternoon.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Healthcare Shares

Why is this ASX 300 stock crashing 18% today?

Investors are rushing to the exits. But why? Let's look into things.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are CSL shares at risk from the Trump tariffs?

How exposed are CSL shares to potential Trump medicinal tariffs?

Read more »

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

What did CSL have to say at Macquarie's 2025 conference?

Does this business have a healthy growth outlook?

Read more »